Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01655108|
Recruitment Status : Unknown
Verified September 2013 by Izelda Maria Carvalho Costa, Brasilia University Hospital.
Recruitment status was: Active, not recruiting
First Posted : August 1, 2012
Last Update Posted : September 25, 2013
This study aims to investigate the effectiveness and safety of mesotherapy for the treatment of female pattern alopecia.
- Sixty female subjects between 18 and 65 years diagnosed with female pattern hair loss will undergo mesotherapy sessions weekly for ten weeks.
- One group will receive 0.5%/2ml minoxidil application and a control group will receive application of placebo (saline 0.9%).
- Biopsy of the scalp, trichogram and trichoscopy (Fotofinder) will be performed before and 08 weeks after treatment as a method objective evaluation of the response
|Condition or disease||Intervention/treatment||Phase|
|Female Pattern Alopecia||Drug: Minoxidil Drug: Saline||Phase 3|
This is a trial that aims to analyze the efficacy and safety of mesotherapy with minoxidil 0,5% versus placebo for androgenetic alopecia in female patients.
The patients and the investigators who analyzes complementary exams are blind.
Clinical criteria, photo, 4mm biopsia, trichogram and trichoscopy are perfomed before patients are randomized into two arms :
Group 1 (Placebo):
30 patients who will have intradermal injections in the scalp of saline 0.9%
Group 2 (Active Drug):
30 patients who will receive intradermal injections in the scalp with minoxidil 0.5%/2ml
Eight weeks after the last session patients will be recruited for repeat the exams and perform a self-assessment of both the effect on hair growth and the effect on hair loss.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||December 2013|
Placebo Comparator: Saline
After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
Active Comparator: Minoxidil 0.5% /2ml
After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
- Increase in hair density [ Time Frame: Sixteen weeks ]Six weeks after the last session of mesotherapy patients will be subjected to control examinations to evaluation of results. Scalp biopsy to determine the terminal-vellus ratio, trichogram to assess the percentage of anagen hair, telogen and dystrophic and Trichoscan will be performed to see if there was improvement in hair density
- Mesotherapy safety [ Time Frame: six months ]
In each session of mesotherapy, blood pressure and cardiac frequency at baseline and 10 min after application of the drug will be measured to assess the safety profile of the solution of minoxidil to 0.5% when injected intradermally.
Any adverse effect reported will be recorded on specific clinical form
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655108
|University of Brasilia|
|Brasilia, Distrito Federal, Brazil, 71917-720|
|Principal Investigator:||Barbara Uzel, M.D||University of Brasilia|
|Study Director:||Izelda Costa, Ph.D||University of Brasilia|